Trial Profile
Randomized Controlled Trial of Infliximab (Remicade) Induction Therapy for Deceased Donor Kidney Transplant Recipients (CTOT-19)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Feb 2023
Price :
$35
*
At a glance
- Drugs Infliximab (Primary) ; Antithymocyte globulin; Diphenhydramine; Loratadine; Methylprednisolone; Mycophenolate mofetil; Paracetamol; Prednisone; Tacrolimus
- Indications Inflammation; Renal transplant rejection
- Focus Therapeutic Use
- Acronyms CTOT-19
- 01 Jan 2023 Primary endpoint has not been met according to results published in the Journal of the American Society of Nephrology
- 01 Jan 2023 Results assessing Efficacy of Infliximab Induction and Increases BK Virus Infection in Deceased Donor Kidney Transplant Recipientspublished in the Journal of the American Society of Nephrology
- 10 Aug 2021 Status changed from active, no longer recruiting to completed.